Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.

The role of IL-6 is supported by preliminary data from a single-arm study in China using Actemra (tocilizumab). Sanofi is leading trials outside of the US, while its development partner ...

Natalizumab eventually ended up as Tysabri, Biogen’s drug for multiple sclerosis, Actemra (tocilizumab) went to Roche as a treatment for rheumatoid arthritis, and Entyvio (vedolizumab ...

Chugai Pharmaceutical Co., Ltd. stock price live, this page displays TYO 4519 stock exchange data. View the 4519 premarket stock price ahead of the market session or assess the after hours quote ...

INCHEON, Korea & JERSEY CITY, N.J., May 27, 2025--Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations ...

Visit a quote page and your recently viewed tickers will be displayed here.

Generally, oral corticosteroids such as prednisone are prescribed first, with another drug, Actemra (tocilizumab), added on. Actemra is an interleukin-6 (IL-6) receptor blocker that blocks an ...